MedTrace Logo

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease

NCT06356779 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2024-04-16

No results posted yet for this study

Summary

This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations.

The primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.

Conditions

  • Oligometastatic Disease
  • Metastases
  • Ablation Techniques
  • Radiotherapy
  • Stereotactic Radiation
  • Surgery

Interventions

PROCEDURE

Local ablative therapy (LAT)

Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions

Sponsors & Collaborators

  • Gitte Fredberg Persson MD PhD

    lead OTHER

Principal Investigators

  • Gitte F Persson, MD PhD · Copenhagen University Hospital Herlev and Gentofte

  • Michael RT Laursen, MD · Copenhagen University Hospital Herlev and Gentofte

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2030-12-31
Completion
2035-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06356779 on ClinicalTrials.gov